| DC9554 |
Cot inhibitor-1 |
Cot inhibitor-1 is a COT/Tpl2 inhibitor. |
|
| DC20933 |
Cotylimide-VI |
Cotylimide-VI (CTL-VI) is a small molecule that perturbs plant hormone strigolactone accumulation and inhibits hypocotyl growth.. |
|
| DC10363 |
Coumestrol
Featured
|
Coumestrol, a phytoestrogen present in soybean products, exhibits activities against cancers, neurological disorders, and autoimmune diseases. It suppresses proliferation of ES2 cells with an IC50 of 50 μM. |
|
| DC21413 |
Cowanin |
Cowanin is a novel natural product from Garcinia speciosa that inhibits the Notch signaling pathway with IC50 of 2.4 uM. |
|
| DC12046 |
CP 105696
Featured
|
CP-105696 is a potent and selective Leukotriene B4 Receptor antagonist, with an IC50 of 8.42 nM. |
|
| DC23320 |
CP 31398 dihydrochloride
Featured
|
CP-31398 is a small molecule p53 reactivator that protects p53 from thermal denaturation, not only reactivates mutant p53 but also induces stabilization of wild type p53. |
|
| DC23610 |
CP-339818 hydrochloride
Featured
|
CP-339818 is a potent, selective, non-peptide KV1.3 channel antagonist with IC50 of 200 nM. |
|
| DC23415 |
CP-481715 |
CP-481715 is a potent and selective CCR1 antagonist with Ki of 9.2 nM and IC50 of 74 nM, lacks intrinsic agonist activity and . |
|
| DC9265 |
CP-640186 hydrochloride
Featured
|
CP-640186 Hcl is an isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; with improved metabolic stability vs CP-610431. |
|
| DC7975 |
CP 640186
Featured
|
CP-640186 is an isozyme-nonselective acetyl-CoA carboxylase inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. |
|
| DC11410 |
CP-671305
Featured
|
CP-671305 is a potent and selective inhibitor of phosphodiesterase 4. |
|
| DC8251 |
CP-724,714 |
CP-724,714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc. Phase 2. |
|
| DC23544 |
CPG-52364 |
CPG-52364 (CPG52364) is an orally available, small molecule TLR7/8/9 antagonist for the treatment of systemic lupus erythematosus and other autoimmune disorders.. |
|
| DC7564 |
CPI 0610(Pelabresib)
Featured
|
CPI 0610 is a potent, selective, and cell-active BET bromodomain inhibitor with IC50 of 39 nM for BRD4-BD1 in TR-FRET assay. |
|
| DC9736 |
CPI1189(REN-1189)
Featured
|
CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. |
|
| DC8001 |
CPI 169 R-enantiomer
Featured
|
CPI-169 R is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2. |
|
| DC8466 |
CPI-169 (racemate）
Featured
|
CPI-169 racemate is the racemate form of CPI-169, which is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2); decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apo |
|
| DC8002 |
CPI-360 (R)
Featured
|
CPI-360 is a compound in design and preparation of wew palladium precatalysts for C-C and C-N cross-coupling reactions. |
|
| DC10593 |
CPI-455 analogue(KDM5 inhibitor)
Featured
|
CPI-455 analogue is a selective inhibitor of KDM5 demethylases. |
|
| DC10591 |
CPI-613
Featured
|
CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer. |
|
| DC22874 |
CPI644 |
CPI644 is a potent, selective, cell-active CBP/EP300 bromodomain inhibitor with IC50 of 0.18 uM for CBP. |
|
| DC20925 |
CPP-115 |
CPP-115 is an orally available, small molecule, next-generation GABA aminotransferase (GABA-AT) inhibitor with Ki of 31 uM, without other GABAergic or off-target activities. |
|
| DC10982 |
CPSI-1306 |
CPSI-1306 (CPSI1306) is an orally available small-molecule MIF antagonist, protects against UVB-induced squamous cell carcinoma, reduces the severity of animal model of multiple sclerosis.. |
|
| DC22061 |
CPT157633 |
CPT157633 is a novel potent, selective PTP1B inhibitor with Ki of 40 nM, shows markedly less activities against a panel of 6 PTPs and 2 dual-specificity phosphatases. |
|
| DC23765 |
CPYPP
Featured
|
CPYPP is a small-molecule inhibitor of the Rac activator DOCK2 with IC50 of 22.8 uM (DOCK2DHR-2-mediated Rac GEF activity), inhibits DOCK2-Rac1 interaction. |
|
| DC12396 |
CR4056
Featured
|
CR4056 (CR 4056, CR-4056) is a novel, orally active imidazoline-2 receptor (I2R) ligand with binding IC50 of 596 nM, also selectively inhibits the enzymatic activity of MAO-A with IC50 of 202.7 nM; increases norepinephrine (NE) tissue levels both in the rat cerebral cortex and lumbar spinal cord, shows ED50 of 5.8 mg/kg in CFA rat model of inflammatory pain; shows high effectivity against bortezomib-induced painful neuropathy in rats. |
|
| DC11380 |
Difelikefalin (CR845)
Featured
|
Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease[1][2]. |
|
| DC20347 |
Crebinostat
Featured
|
Crebinostat is a novel cognitive enhancer that inhibits class I HDAC/1/2/3 (IC50=0.7/1.0/2.0 nM), class IIb HDAC6 (IC50=9.3 nM) with weaker inhibition of the class I HDAC8 and no significant inhibition of the class IIa HDAC/4/5/7/9; potently induces acetylation of both histone H3 and histone H4 as well as enhanced the expression of the CREB target gene Egr1 in cultured mouse primary neurons; upregulates Bdnf and Grn, and downregulates Mapt (tau) gene expression-genes; brain penetrant. |
|
| DC22208 |
cRIPGBM |
cRIPGBM (RIPGBM derivative cRIPGBM, RIPGBM-18) is a metabolite of RIPGBM induces apoptosis in GBM CSCs (EC50=68 nM in GBM 1 cells) by interacting with RIPK2 (Kd=2.3 uM). |
|
| DC21980 |
Crisdesalazine |
Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro. |
|
